Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study
Authors
Michael W. Marx
Dominic A. Ritacco
Stephan Chalon (ORCID: https://orcid.org/0000-0002-9306-1851)
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study
Michael W. Marx, Dominic A. Ritacco, Stephan Chalon, Benoît Bestgen et al.
Citations
4 citations
Journal
The Lancet Infectious Diseases
Topics
Malaria Research and Control
Field-Weighted Citation Impact (FWCI)
2.17
article
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study
Michael W. Marx, Dominic A. Ritacco, Stephan Chalon, Benoît Bestgen, Amina Haouala, Stacey Llewellyn, Didier Leroy, Tomas Yeo, Vandana Thathy, Bridget E. Barber, Ilaria Di Resta, Andrea Kuemmerle, Maja Szramowska, Paul Griffin, Sam Jones, David A. Fidock, Denis Gossen, Catalina Barceló, Jason D. Lickliter, Rebecca Webster
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Infectious DiseasesVol. 25(5)
Institutions
The University of Queensland (AU), QIMR Berghofer Medical Research Institute (AU), Columbia University Irving Medical Center (US), MinebeaMitsumi (Germany) (DE), 4D Pharma (United Kingdom) (GB), Asklepios Klinik Langen (DE), Mangar Health (United Kingdom) (GB), Medicines for Malaria Venture (CH)
Funders
Bill and Melinda Gates Foundation, Medicines for Malaria Venture